NUVL
Nuvalent, Inc. NASDAQ$102.62
Mkt Cap $7.5B
52w Low $63.55
79.0% of range
52w High $113.02
50d MA $101.82
200d MA $94.95
P/E (TTM)
-16.9x
EV/EBITDA
-672.4x
P/B
5.8x
Debt/Equity
0.0x
ROE
-34.1%
P/FCF
-26.6x
RSI (14)
—
ATR (14)
—
Beta
1.31
50d MA
$101.82
200d MA
$94.95
Avg Volume
564.9K
About
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 i…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.48 | -1.29 | +12.8% | 103.93 | -0.9% | -1.9% | -2.5% | -3.6% | -1.2% | -3.7% | -6.9% | — |
| Oct 30, 2025 | AMC | -1.39 | -1.70 | -22.3% | 98.17 | +1.7% | +1.2% | -5.2% | -7.3% | -6.2% | -2.3% | +8.4% | — |
| Aug 7, 2025 | AMC | -1.27 | -1.31 | -3.1% | 72.16 | -0.2% | +2.7% | +3.9% | +6.2% | +8.4% | +6.4% | +10.6% | — |
| May 8, 2025 | AMC | -1.14 | -1.18 | -3.5% | 71.60 | +0.7% | -2.4% | +2.8% | -0.3% | -0.8% | -0.8% | +6.3% | — |
| Feb 27, 2025 | AMC | -1.04 | -1.05 | -1.0% | 74.91 | -1.2% | +0.1% | -5.2% | -4.4% | -3.9% | -2.6% | -5.3% | — |
| Nov 12, 2024 | AMC | -0.93 | -1.28 | -37.0% | 90.99 | +0.6% | -0.7% | -0.9% | -4.5% | -3.6% | +0.1% | -4.6% | — |
| Aug 8, 2024 | AMC | -0.76 | -0.88 | -15.8% | 70.24 | +0.2% | -0.4% | +2.7% | +1.7% | -0.3% | +2.4% | +27.1% | — |
| May 9, 2024 | AMC | -0.67 | -0.69 | -3.0% | 67.52 | -1.2% | -3.0% | -2.1% | +0.7% | +6.2% | +7.6% | +18.6% | — |
| Feb 27, 2024 | AMC | -0.59 | -0.62 | -5.1% | 88.99 | -0.3% | -4.1% | -5.5% | -2.0% | -4.5% | -8.5% | -15.6% | — |
| Nov 14, 2023 | AMC | -0.59 | -0.59 | +0.0% | 58.81 | -2.1% | +0.3% | -1.3% | +1.6% | +2.6% | +2.0% | +34.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.24 | $108.45 | +0.2% | -1.0% | +0.6% | -0.2% | -3.5% | -3.9% |
| Apr 8 | Wedbush | Maintains | Outperform → Outperform | — | $102.25 | $105.65 | +3.3% | +2.7% | +2.3% | +0.5% | +1.4% | +2.7% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $103.93 | $102.96 | -0.9% | -1.9% | -2.5% | -3.6% | -1.2% | -3.7% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $101.41 | $104.00 | +2.6% | +2.4% | +4.3% | +3.4% | +4.3% | +2.7% |
| Nov 18 | Baird | Maintains | Outperform → Outperform | — | $108.00 | $104.38 | -3.4% | -3.5% | -0.8% | +0.0% | -2.0% | +1.4% |
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $108.00 | $104.38 | -3.4% | -3.5% | -0.8% | +0.0% | -2.0% | +1.4% |
| Nov 18 | Goldman Sachs | Maintains | Buy → Buy | — | $108.00 | $104.38 | -3.4% | -3.5% | -0.8% | +0.0% | -2.0% | +1.4% |
| Nov 17 | Stifel | Maintains | Buy → Buy | — | $96.50 | $93.30 | -3.3% | +11.9% | +8.0% | +11.0% | +11.9% | +9.7% |
| Nov 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $96.50 | $93.30 | -3.3% | +11.9% | +8.0% | +11.0% | +11.9% | +9.7% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $96.50 | $93.30 | -3.3% | +11.9% | +8.0% | +11.0% | +11.9% | +9.7% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing content provided is incomplete—it contains only technical HTML/XML metadata without any actual material event details or substantive disclosure for Nuvei (NUVL).
Apr 7
8-K
Nuvalent, Inc. -- 8-K Filing
Nuvalent (NUVL) reported 2025 financial results and reaffirmed key pipeline milestones while advancing commercial preparations for potential U.S. product launches in its targeted cancer therapy programs.
Feb 26
Data updated apr 26, 2026 4:11pm
· Source: massive.com